✓
Open
3 Jul 2024
✓
Close
5 Jul 2024
3
Allotment
—
✓
Listing
Wed, Jul 10, 2024
Price Band
₹960 to ₹1008
Issue Size
1,93,75,070 shares (agg. up to ₹1,952 Cr)
Lot Size
14 Shares
Listing Date
Wed, Jul 10, 2024
Latest GMP
₹300
Est. Gain
29.76%
✦ AI Insight
GMP Trend
10-07-2024₹300Est. ₹1308+29.76%
09-07-2024₹300Est. ₹1308+29.76%
08-07-2024₹365Est. ₹1373+36.21%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 48.13x |
Restated Financials (₹ Cr.)
| Period Ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Assets | 7,806.16 | 6,672.53 | 6,063.47 |
| Total Income | 6,715.24 | 6,031.72 | 5,918.86 |
| Profit After Tax | 527.58 | 561.85 | 702.56 |
| NET Worth | 2,952.28 | 2,501.13 | 1,987.55 |
| Reserves and Surplus | 2,722.40 | 2,293.77 | 1,791.03 |
| Total Borrowing | 2,091.94 | 2,202.42 | 2,102.19 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Innova Captab Ltd. | Mainboard | ₹570.00 Cr | ₹448 | 31.64 | ₹541.40 | +20.85% | ₹1,171.80 |
| Blue Jet Healthcare Ltd. | Mainboard | ₹840.27 Cr | ₹346 | 37.49 | ₹413.40 | +19.48% | ₹581.50 |
| Valiant Laboratories Ltd. | Mainboard | ₹152.46 Cr | ₹140 | 15.71 | ₹170.25 | +21.61% | ₹114.13 |
| Concord Biotech Ltd. | Mainboard | ₹1,550.52 Cr | ₹741 | 32.29 | ₹942.80 | +27.23% | ₹1,470.50 |
| Medicamen Organics Ltd. | SME | ₹10.54 Cr | ₹34 | 30.53 | ₹144.70 | +325.59% | ₹26.50 |
| Quest Laboratories Ltd. | SME | ₹43.16 Cr | ₹97 | 23.03 | ₹147.35 | +51.91% | ₹82.00 |
| Zenith Drugs Ltd. | SME | ₹40.68 Cr | ₹79 | 18.4 | ₹105.15 | +33.10% | ₹48.85 |
| Sunrest Lifescience Ltd. | SME | ₹10.85 Cr | ₹84 | 12.33 | ₹79.80 | -5.00% | ₹39.00 |
| Mono Pharmacare Ltd. | SME | ₹14.84 Cr | ₹28 | null | ₹30.45 | +8.75% | ₹9.00 |
| Shelter Pharma Ltd. | SME | ₹16.03 Cr | ₹42 | 5.62 | ₹41.96 | -0.10% | ₹31.00 |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment and/or prepayment of all or a portion of certain outstanding borrowings availed by our Company | 800.00 |
| 2 | General corporate purposes | 41.14 |
About Emcure Pharmaceuticals IPO
Updated on Aug 12, 2026
Contact Details
Emcure Pharmaceuticals Ltd. AddressPlot No.P-1 and P-2IT-BT Park, Phase II, M.I.D.C.HinjawadiPune, Maharashtra, 411057+91 20 3507 0033investors@emcure.co.inVisit Website